Weekly injection that activates GLP-1 and glucagon receptors. Approved in China for weight management and type 2 diabetes; not approved in the US or the EU.
Regulatory status
In clinical trials
Family
Dual GLP-1 and glucagon receptor agonist
Scientific evidence
Moderate
Number of findings
1
Where it acts
Digestive and weight · Hormones and metabolism
Also known as
mazdutide, IBI362, LY3305677
Regulatory status
FDA (US): Not approved.
EMA (EU): Not approved. (Approved in China by the NMPA in 2025 for chronic weight management and for type 2 diabetes.)
Dose
There is no established dose in humans per FDA/EMA. In the phase 3 GLORY-1 trial, 4 or 6 mg subcutaneously once a week was used (NEJM 2025).
Safety
Digestive effects are frequent: nausea in 32.5% (4 mg) and 50.5% (6 mg) in GLORY-1, along with vomiting and diarrhea. Outside China, use only in clinical trials or research, under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
Weight loss in Chinese adults with overweight or obesity
improvesModerateRCT (AA)in people
−14% weight
GLORY-1 trial (610 adults): at 32 weeks the loss was 10.1% (4 mg) and 12.6% (6 mg); at 48 weeks, 14.0% with 6 mg vs +0.3% with placebo. Chinese population only.
Its GLP-1 part reduces appetite, improves glucose, and slows gastric emptying. Its glucagon part increases energy expenditure and fat burning in the liver. The combination aims for more weight loss and less liver fat than GLP-1 alone.
What the evidence says
In people
Weight loss in Chinese adults with overweight or obesity. GLORY-1 trial (610 adults): at 32 weeks the loss was 10.1% (4 mg) and 12.6% (6 mg); at 48 weeks, 14.0% with 6 mg vs +0.3% with placebo. Chinese population only. PubMed 40421736